Strong Ph I/II data for MolMed's TK in acute leukemia

Italian drugmaker MolMed says that TK, its cell-based therapy, showed significant survival improvement of patients affected by high-risk acute  leukemia receiving bone marrow transplants from a partially compatible  family donor.

Published in the April issue of The Lancet Oncology, the Phase I/II  study investigated the infusion of suicide gene-engineered donor  lymphocytes after family haploidentical hemopoietic transplantation for  leukemia in 54 adult patients.

In this context, the introduction of TK therapy allows the use of  add-backs of donor T lymphocytes that promote a rapid and wide immune  reconstitution, abating transplant-related mortality and permitting  long-term survival, the firm noted. It added that the intention-to-treat  analysis shows that TK therapy proved to greatly improve safety and  efficacy of haplo-transplants, thus enabling feasibility and  effectiveness of transplants in adult patients from partially  incompatible family donors.